WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 565606
CAS#: N/A
Description: Ibr-7 is a novel btk inhibitor, inhibiting non-small cell lung cancer (nsclc) via targeting mtorc1/s6
MedKoo Cat#: 565606
Name: Ibr-7
CAS#: N/A
Chemical Formula: C24H22BrN7O2
Exact Mass: 519.1018
Molecular Weight: 520.391
Elemental Analysis: C, 55.39; H, 4.26; Br, 15.35; N, 18.84; O, 6.15
Synonym: Ibr-7; Ibr 7; Ibr7
IUPAC/Chemical Name: (R)-1-(3-(4-Amino-3-(5-phenoxypyridin-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-bromoprop-2-en-1-one
InChi Key: IJNQTKBEQIQXHA-MRXNPFEDSA-N
InChi Code: InChI=1S/C24H22BrN7O2/c1-15(25)24(33)31-11-5-6-16(13-31)32-23-20(22(26)28-14-29-23)21(30-32)19-10-9-18(12-27-19)34-17-7-3-2-4-8-17/h2-4,7-10,12,14,16H,1,5-6,11,13H2,(H2,26,28,29)/t16-/m1/s1
SMILES Code: C=C(Br)C(N1C[C@H](N2N=C(C3=NC=C(OC4=CC=CC=C4)C=C3)C5=C(N)N=CN=C52)CCC1)=O
1: Zhang B, Wang L, Zhang Q, Yan Y, Jiang H, Hu R, Zhou X, Liu X, Feng J, Lin N. The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling. Mol Oncol. 2019 Apr;13(4):946-958. doi: 10.1002/1878-0261.12454. Epub 2019 Feb 22. PubMed PMID: 30663221; PubMed Central PMCID: PMC6441926.